Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences said that its investigational therapy in development for the treatment of people with cystic fibrosis who have pulmonary pseudomonas aeruginosa improved symptoms in a Phase III trial.
Subscribe to our email newsletter
In this study, a 28-day treatment course of antibiotic aztreonam lysine for inhalation improved respiratory symptoms as assessed by the cystic fibrosis questionnaire-revised (CFQ-R), a patient-reported outcome tool.
Aztreonam lysine also improved pulmonary function in this study, as measured by relative improvement of forced expiratory volume in one second (FEV1), a standard measure of lung function. The data were presented by George Retsch-Bogart, associate professor of pediatrics at the University of North Carolina.
Mr Retsch-Bogart, said: “Cystic fibrosis causes a type of chronic lung disease that is characterized by recurring or persistent bacterial infection, which leads to gradually declining lung function, exercise capacity and quality of life. These study results are particularly encouraging, given that patients experienced meaningful improvements as measured by both patient-reported respiratory symptoms and also traditional pulmonary function endpoints such as FEV1.”